Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Rhea-AI Summary
Tango Therapeutics (NASDAQ:TNGX) announced that its management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT. A live webcast and a 90-day replay will be accessible via the Investors section of the company’s website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 11 | 2Q26 earnings report | Positive | -4.9% | Early clinical data and cash balance contrasted with a larger quarterly loss |
| Aug 06 | Leadership transition | Negative | -6.7% | Executive chair departure preceded a negative price reaction and leadership transition |
| Jun 22 | Board appointment | Positive | -0.4% | Board appointment and commercialization focus were followed by a negative reaction |
| Jun 09 | Public offering | Negative | -9.1% | Upsized public offering and expected proceeds accompanied a sharp negative reaction |
| Jun 08 | Public offering | Negative | +2.0% | Proposed equity offering drew a positive reaction despite dilution risk |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions diverged from positive clinical and management news but aligned with negative leadership and offering events.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT.
The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
Investors:
Elizabeth Hickin
ehickin@tangotx.com
Media:
1AB
Amanda Lazaro
amanda@1abmedia.com
